



Biosergen publishes interim report for first quarter 2023

Wednesday, May 31, 2023: Biosergen AB ("Biosergen" or the "Company") thereby publishes the interim report for the first quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)

Summary of the Interim Report for Q1 2023

TSEK	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec
Profit/loss			
Other income	5,315	1,317	5,183
Profit/loss before depreciation (EBITDA)	-5,029	-5,018	-34,129
Operating profit/loss before net financials	-5,029	-5,018	-34,129
Net financials	2	3	81
Netprofit/loss for the period	-5,027	-5,015	-34,048
Earnings per share (SEK)	-0.18	-0.18	-1.09

Highlights during Q1 2023

- March 29, Biosergen provides Phase 2 clinical development strategy update.
- March 13, Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
- January 16, Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial.

Highlights after the period

There have been no highlights after the period

The Financial report can be found on our website: <http://biosergen.net/investors/filings>

For further information about Biosergen, please contact:

Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net

Niels Laursen, CFO
Telephone: +45 4014 5059
Email: niels.laursen@biosergen.net

Certified Adviser

Erik Penser Bank

Telefon: +46 8 463 8000

E-mail: certifiedadvisor@penser.se

ABOUT BIOSERGEN

Biosergen is a clinical stage biotechnology company that employs all its organizational and financial resources on the clinical development of BSG005. BSG005, a polyene macrolide, is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, and being completely free of the kidney toxicity hampering other drugs in its class. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care. The Company is also developing BSG005 *Nano* where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 *Nano Oral* is an extension of BSG005 *Nano*. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen is granted orphan drug status for BSG005 in the United States.